Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01369121 · ClinicalTrials.gov registry record · Phase 1
Tolerability Study of Xerecept® in Pediatric Patients
A Phase 1 study, sponsored by Celtic Pharma Development Services.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01369121 is a Phase 1 study that was terminated before completion, run by Celtic Pharma Development Services. The registered enrollment target is 15 participants.
The verdict
NCT01369121, a Phase 1 study, was terminated before completion, sponsored by Celtic Pharma Development Services.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study is being conducted to evaluate the safety and tolerability of Xerecept® in children with central nervous system tumors and to identify appropriate doses of Xerecept® to be used in subsequent pediatric clinical trials.
Interventions
- DRUG XERECEPT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2010-06 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01369121
The ClinicalTrials.gov registry entry for NCT01369121 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celtic Pharma Development Services, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XERECEPT is the first listed.
NCT01369121 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01369121 about?
NCT01369121 is a clinical study titled "Tolerability Study of Xerecept® in Pediatric Patients". This study is being conducted to evaluate the safety and tolerability of Xerecept® in children with central nervous system tumors and to identify appropriate doses of Xerecept® to be used in subsequent pediatric clinical trials.
What is the current status of trial NCT01369121?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2010-06. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01369121?
The interventions under investigation include: XERECEPT (DRUG).
Who is sponsoring clinical trial NCT01369121?
This trial is sponsored by Celtic Pharma Development Services, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.